Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
Janssen to buy licence for autoimmune...
Home  »  Community News  »  Janssen to buy licen...
Janssen to buy licence for autoimmune diseases development programme from Novo Nordisk
Pharma News
, ,

Novo Nordisk A/S, a global healthcare company, has signed an agreement with Janssen Biotech, Inc. (Janssen) under which Janssen will acquire an exclusive global licence to further develop and commercialise a clinical programme focused on therapy within autoimmune diseases. The programme targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor). Terms of the agreement have not been disclosed.

The agreement is subject to final clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the US Department of Justice Antitrust Division and the Federal Trade Commission.

Leave a reply

You must be logged in to post a comment.